findmyKOL
Clinical trialNCT01076010CompletedPhase 3Interventional

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

SponsorAVEO Pharmaceuticals, Inc.Enrollment277Advanced Renal Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

75 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bulgaria
  • Site 403

    Plovdiv, Bulgaria

  • Site 400

    Sofia, Bulgaria

  • Site 404

    Sofia, Bulgaria

  • Site 401

    Varna, Bulgaria

  • Site 402

    Veliko Tarnovo, Bulgaria

Canada
  • Site 110

    Montreal, Quebec, Canada

Chile
  • Site 122

    Santiago, Chile

  • Site 123

    Temuco, Chile

Czechia
  • Site 411

    Prague, Czechia

France
  • Site 133

    Saint-Herblain, France

Hungary
  • Site 423

    Budapest, Hungary

  • Site 421

    Kaposvár, Hungary

  • Site 422

    Pécs, Hungary

India
  • Site 156

    Ahmedabad, Gujarat, India

  • Site 151

    Nashik, Maharashtra, India

  • Site 153

    Pune, Maharashtra, India

  • Site 191

    Jaipur, Rajasthan, India

  • Site 152

    Vellore, Tamil Nadu, India

  • Site 158

    Lucknow, Uttar Pradesh, India

  • Site 150

    Kolkata, West Bengal, India

  • Site 154

    Delhi, India

Italy
  • Site 160

    Arezzo, Italy

  • Site 161

    Pavia, Italy

  • Site 162

    Roma, Italy

Poland
  • Site 432

    Bialystok, Poland

  • Site 434

    Bydgoszcz, Poland

  • Site 431

    Gdansk, Poland

  • Site 435

    Olsztyn, Poland

  • Site 433

    Poznan, Poland

  • Site 430

    Warsaw, Poland

  • Site 436

    Warsaw, Poland

Romania
  • Site 444

    Brasov, Romania

  • Site 440

    Bucharest, Romania

  • Site 441

    Bucharest, Romania

  • Site 443

    Bucharest, Romania

  • Site 442

    Timișoara, Romania

Russia
  • Site 459

    Ufa, Bashkortostan Republic, Russia

  • Site 451

    Chelyabinsk, Russia

  • Site 452

    Kazan', Russia

  • Site 453

    Moscow, Russia

35 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2010
Primary completion
31 Jul 2014
Completion
31 Jul 2014
Last update posted
5 Oct 2020
Registered enrollment
277
Registry id
NCT01076010

Cross-registrations

EU-CTR / CTIS (EudraCT)2009-015987-32

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.